Ysios Capital

Ysios Capital stands as Spain's premier venture capital organization specializing in life sciences investments. Established in 2008, the firm has grown to manage an impressive portfolio exceeding USD 420 million across three dedicated funds. Their investment strategy centers on identifying and supporting innovative companies developing breakthrough therapeutic solutions and cutting-edge platform technologies in the biotechnology and pharmaceutical sectors. With headquarters in Barcelona and operations throughout Europe, Ysios has positioned itself as a crucial funding partner for companies navigating the complex journey from scientific discovery to commercial success.

The firm's investment approach focuses primarily on early to mid-stage life science ventures with exceptional potential for disruption and market impact. Ysios typically engages with companies from seed rounds through Series B financing, providing not just capital but also strategic guidance during critical growth phases. Their portfolio reflects a diverse range of therapeutic areas including oncology, neurodegenerative diseases, metabolic disorders, and rare diseases. The investment team applies rigorous scientific and commercial evaluation to identify opportunities with compelling biological rationales, strong intellectual property positions, and clear paths to value creation.

Ysios Capital is helmed by a distinguished leadership team combining extensive experience in venture capital, pharmaceutical development, and company building. The partners and investment professionals bring decades of collective expertise from roles in global pharmaceutical corporations, biotech startups, and financial institutions. This multidisciplinary background enables them to provide portfolio companies with valuable insights on drug development strategies, regulatory pathways, and business development opportunities. Their hands-on approach to investment management has earned them recognition as value-added investors who actively contribute to their portfolio companies' strategic direction and operational execution.

Throughout its history, Ysios has established a track record of successful investments in companies that have achieved significant clinical milestones, strategic partnerships, and exits. Notable portfolio companies have secured licensing deals with major pharmaceutical companies, completed successful IPOs, and delivered innovative therapies to patients. The firm maintains strong connections within the European and American life sciences ecosystems, facilitating valuable cross-border collaborations and follow-on investment opportunities. As the European biotech sector continues to mature, Ysios Capital remains committed to fueling innovation in life sciences and supporting entrepreneurs working to address significant unmet medical needs through groundbreaking scientific approaches.